GEN-MKT-18-7897-A
May 7, 2020 | Biopharma, Blogs, Pharma | 0 comments
For many of you working to develop gene therapy drugs, you know that the time to market the drug is critical. Because gene therapeutics cure diseases by targeting specific genes, it is a constant race to see who develops the drug first. Unlike other classes of drugs where multiple medications can be used to treat a disease, whoever is first to develop a gene therapy drug wins.
When it comes to adeno-associated virus-based gene therapies, there is a lack of reliable and reproducible methods to consistently produce them. One of the key challenges you face when analyzing AAVs is determining whether the therapeutic transgene payload has been successfully incorporated into the AAV vector product.
During the manufacturing of AAV vectors, capsids containing the full payload of transgenes are produced. There is also a high percentage of capsids that might not incorporate any of the transgenes (empty), or contain fragments of the transgene (partial), that are produced as well. The presence of these impurities could increase immunogenicity or inhibit transduction of full capsids by competing for vector binding sites on cells. That is why successful incorporation of the transgene is critical for the efficacy and safety of gene therapies.
SCIEX has developed a breakthrough analytical method that is able to detect with great precision whether the AAV capsids are full, partially full or empty.
You will discover:
This is instrumental in improving and streamlining the development and production process for your AAV-based therapeutics. By giving you the right analytics, you will be able to develop better quality and safer products, all while reducing the cost to manufacture.
With the prospect of shorter analysis time and better analytics, request a copy of our technical note dedicated to teaching you all about our novel method. Find out how you can improve your drug development process with this method now.
PFAS analysis is complex, but expert guidance doesn’t have to be. In this episode of our ‘Ask the PFAS expert series’, we’re joined by Michael Scherer, Application Lead for Food and Environmental, to answer the most pressing questions in PFAS analysis. From why LC-MS/MS systems are the gold standard for analyzing diverse PFAS compounds, to which EU methods deliver reliable results for drinking water, and to practical steps to prevent contamination, Michael shares actionable insights to help laboratories achieve accuracy, consistency, and confidence in their workflows.
During an LC-MS/MS experiment, traditional fragmentation techniques like collision-induced dissociation (CID) have long been the gold standard. Electron-activated dissociation (EAD) is emerging as a transformative tool that enhances structural elucidation, particularly for complex or labile metabolites.
In the field of food chemistry and health, Prof. Nils Helge Schebb and his team at the University of Wuppertal are at the forefront of applying cutting-edge analytical methods to investigate how dietary components affect inflammation and chronic disease. Their work focuses on lipid mediators, particularly oxylipins, and how these molecules can be precisely measured and interpreted using liquid chromatography-tandem mass spectrometry (LC-MS).
Posted by
You must be logged in to post a comment.
Share this post with your network